Apellis Pharmaceuticals, Inc.
General ticker "APLS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.1B (TTM average)
Apellis Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 18.8%.
Estimated limits based on current volatility of 1.7%: low 20.91$, high 21.86$
Factors to consider:
- Total employees count: 767 as of 2022
- Top business risk factors: Insufficient funding, Product commercialization failure, Regulatory and compliance, Geopolitical risks, Litigation risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [18.26$, 45.96$]
- 2025-12-31 to 2026-12-31 estimated range: [15.99$, 40.70$]
Financial Metrics affecting the APLS estimates:
- Negative: with PPE of -21.0 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -2.15 <= 0.33
- Positive: Investing cash flow per share per price, % of -0.01 > -0.66
- Negative: negative Net income
- Positive: 18.93 < Shareholder equity ratio, % of 25.82 <= 41.86
- Negative: negative Industry operating cash flow (median)
Short-term APLS quotes
Long-term APLS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $75.42MM | $396.59MM | $781.37MM |
| Operating Expenses | $670.03MM | $913.71MM | $946.35MM |
| Operating Income | $-594.61MM | $-517.12MM | $-164.98MM |
| Non-Operating Income | $-56.89MM | $-9.38MM | $-31.74MM |
| Interest Expense | $32.63MM | $29.58MM | $40.39MM |
| R&D Expense | $387.24MM | $354.39MM | $327.57MM |
| Income(Loss) | $-651.50MM | $-526.50MM | $-196.72MM |
| Taxes | $0.67MM | $2.13MM | $1.16MM |
| Profit(Loss)* | $-652.17MM | $-528.63MM | $-197.88MM |
| Stockholders Equity | $169.87MM | $194.52MM | $228.54MM |
| Inventory | $85.71MM | $146.36MM | $82.48MM |
| Assets | $760.22MM | $788.73MM | $885.05MM |
| Operating Cash Flow | $-513.75MM | $-594.74MM | $-87.87MM |
| Capital expenditure | $1.52MM | $0.77MM | $0.40MM |
| Investing Cash Flow | $59.89MM | $-0.67MM | $-0.40MM |
| Financing Cash Flow | $365.66MM | $394.50MM | $149.24MM |
| Earnings Per Share** | $-6.15 | $-4.45 | $-1.60 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.